Kennedy Capital Management’s Atrium Therapeutics RNA Stock Holding History
Bought
Maintained
Sold
Other funds holding RNA
Kennedy Capital Management's RNA Position: Q3 2026 in Review
Kennedy Capital Management increased its Atrium Therapeutics (RNA) stake by 75% in Q3 2026, buying an estimated $310K and bringing the position to 61,255 shares worth $507K. The position accounts for 0.01% of the portfolio, ranked #529.
Kennedy Capital Management first reported a position in RNA in Q1 2026 and has held it in 3 quarters since. 145 funds tracked by Wall St. Rank hold RNA as of Q3 2026.
- Kennedy Capital Management held 61,255 shares of Atrium Therapeutics worth $507K as of Q3 2026.
- Kennedy Capital Management bought 26,276 Atrium Therapeutics shares in Q3 2026, an estimated $310K.
- Atrium Therapeutics made up 0.01% of Kennedy Capital Management's portfolio in Q3 2026, its #529 holding.
- Kennedy Capital Management first reported a position in Atrium Therapeutics in Q1 2026 and has held it in 3 quarters since.
- 145 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q3 2026.
Based on Kennedy Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.